Glaxo's Tykerb fights breast cancer stem cells in study

04/17/2008 | Reuters · MarketWatch

Tykerb, GlaxoSmithKline's cancer treatment, was effective in reducing tumor-causing cancer stem cells in breast cancer patients undergoing therapy before surgery, U.S. scientists reported. The findings of the company-funded study suggest that "targeting the stem cells may be more effective and also prevent some of the unpleasant side effects associated with conventional chemotherapy treatment," one of the researchers said.

View Full Article in:

Reuters · MarketWatch

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Executive Officer
Center for Improving Value in Healthcare
Denver, CO
Quality Program Manager II, State Programs
Tufts Health Plan
Watertown, MA
Associate Director, Promotion Integrity
Bristol-Myers Squibb
Plainsboro, NJ
Vice President, Medicare Advantage
BCBS-Louisiana
Baton Rouge, LA
Director, Global Integrity and Compliance, Pharmaceuticals
Alcon
Fort Worth, TX